Username:

Password:
GO

ADVANCES IN GENETIC MEDICINE
Thursday 3rd December 2020
Friends House, 173-177 Euston Road, London NW1 2BJ

This meeting is sponsored by:



OVERVIEW
Advanced Therapies such as genetic medicines or genetically engineered cell-based drugs are coming of age, with the recent approvals of CAR T-cell therapies and Luxterna, Zolgensma, Onpattro and Exondys 51 demonstrating the validity of these approaches in the treatment of a range of medical conditions. Such therapies offer the potential to treat and even cure previously intractable diseases, for example those associated with specific genetic abnormalities.

This meeting that will provide an overview of emerging approaches the field of genetic medicines through a range of project presentations on cutting-edge modalities and their application in a range of therapeutic areas.

In addition to the confirmed speakers there will be an opportunity for early career researchers to present posters on topics aligned to this theme, with a flash talk session included in the programme to allow selected presenters to summarise their key message in front of the full audience.

Confirmed Speakers:

  • Brian Bigger, University of Manchester - Haematopoietic stem cell gene therapies for neurological diseases: How do we widen participation and scope?
  • David Blakey, MiNA Therapeutics - Small Activating RNAs a novel therapeutic approach to upregulate target genes building on the clinical success of siRNAs
  • Lewis Brayshaw, GSK- Development of next-generation T cell therapies: the immune system meets synthetic and chemical biology
  • Anna Perdrix Rosell, SixFol Bio - Building targeted delivery systems - increasing safety and efficacy for oligonucleotide-based therapeutics in oncology
  • Zandy Forbes, MeiraGTx - Title to follow
  • Lucie Bruijn, AveXis (a Novartis Company) - Title to follow

 

NOTE: We are continuing to plan to hold this as a face to face meeting at Friends House, an ethical and sustainable conference venue.
However should the developing situation make this impossible, for example government and company policies, we will switch to an online format.

OVERVIEW
PROGRAMME